ArticleScientific reports2018
Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 45 citations in OpenAlex.
- Liposomal drug delivery system for anti-inflammatory treatment after cataract surgery: a phase I/II clinical trial.Drug delivery and translational research · 2022Trial
- Therapeutic Effect of Baicalin-Loaded Thermosensitive Liposomal Hydrogel in Autoimmune Uveitis.ACS omega · 2026Article
- Advances in the management of ocular anterior segment diseases using biomaterials-based drug delivery systems.Journal of biomaterials applications · 2026Review
- An Update on Novel Drug Delivery Systems for the Management of Glaucoma.Pharmaceutics · 2025Review
- Steroidal nanoformulations for the treatment of uveitis: potential, promises and future perspectives.International ophthalmology · 2024Review
- A New Era in Ocular Therapeutics: Advanced Drug Delivery Systems for Uveitis and Neuro-Ophthalmologic Conditions.Pharmaceutics · 2023Review
- Ocular Drug Delivery: a Comprehensive Review.AAPS PharmSciTech · 2023Review
- Evaluation of a steroid delivery system to mitigate the severity of proliferative vitreoretinopathy in a minipig model.Frontiers in ophthalmology · 2023Article
- Nanotechnology for the Treatment of Allergic Conjunctival Diseases.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Sustained subconjunctival drug delivery systems: current trends and future perspectives.International ophthalmology · 2020Review
- Preparation andIranian journal of basic medical sciences · 2020Article
- Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations.Pharmaceutics · 2020Review
- Characterisation of the inflammatory cytokine and growth factor profile in a rabbit model of proliferative vitreoretinopathy.Scientific reports · 2019Article
- The availability of drug by liposomal drug delivery : Individual kinetics and tissue distribution of encapsulated and released drug in mice after administration of PEGylated liposomal prednisolone phosphate.Investigational new drugs · 2019Article
- Therapeutic implications of nanomedicine for ocular drug delivery.Drug discovery today · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-infectious anterior uveitis (AU) is a potentially sight threatening inflammatory condition. The current gold standard for treatment is topical steroids, but low ocular bioavailability and compliance issues with the intensive dosing regimen limit the efficacy of this treatment. Liposomes as a drug delivery system may help to overcome these problems. We studied the efficacy of a PEG-liposomal formulation of liposomal steroids, administered as a single subconjunctival dose, in the treatment of experimental uveitis in rabbit eyes. Rabbits that received subconjunctival liposomal triamcinolone acetonide phosphate (LTAP) or liposomal prednisolone phosphate (LPP) had significantly lower mean inflammatory scores than untreated controls on Day 4 after induction of uveitis (LPP vs controls, p = 0.049) and 8 (LPP vs controls, p = 0.007; LTAP vs controls, p = 0.019), and lower scores than rabbits given topical PredForte1% 4 times a day on Day 8 (p = 0.03). After antigen rechallenge, the subconjunctival liposomal steroid groups continued to have greater suppression of inflammation than untreated controls on Day 11 (p = 0.02). Localization of liposomes in inflamed ocular tissue was confirmed by histology and immunostaining, and persisted in the eye for at least one month. Our study demonstrates that a single subconjunctival injection of liposomal steroids induces effective and sustained anti-inflammatory action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.